Key facts
- Javara’s last known valuation is $98.6M (May 2025).
- It has raised $59.7M across 6 recorded rounds; the latest was Early Stage VC ($6.6M) in May 2025.
- Notable investors include General Atlantic, FCA Venture Partners.
- Javara has filed 6 Form Ds with the SEC since 2019, most recently May 2025 ($6.6M sold to 23 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Javara
Funding rounds
6 roundsAbout Javara
Operator of an integrated research organization intended to change and optimize the clinical research experience. The company's model centers on integrating clinical research at the point of care alongside trusted providers to increase clinical trial participation and contribute timely data, thereby reducing the drug development time cycle, enabling healthcare organizations to benefit from improved clinical trial access and outcomes.
- Sector
- Healthcare
- HQ
- Winston-Salem, NC, United States
- Founded
- 2018
- Employees
- 187
- Website
- javararesearch.com/
- Ownership
- Privately Held (backing)
Javara doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Javara shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Javara in its N-PORT filings yet. We sweep new filings monthly.